Sitero has acquired studyOS, a provider of an AI-powered data platform for clinical trials, for an undisclosed amount. This acquisition marks a strategic expansion for Sitero into advanced clinical trial management and oversight capabilities.
studyOS specializes in building a data platform that leverages AI-powered Clinical Trial Agents. These agents automate the centralizing, analyzing, and visualizing of clinical trial data. This technology is designed to help ensure patient safety, uphold study protocols, and accelerate the process of bringing new drugs to market. Its offerings include automated clinical oversight and risk management with complete audit trails, seamlessly ingesting data from various clinical systems like EDC, eCOA, IRT, and labs to provide centralized visibility and ensure compliance with regulatory standards such as ICH E6(R3).
This acquisition is highly strategic, as studyOS’s innovative AI and automation tools are expected to integrate with Sitero’s existing suite of clinical research solutions. The synergy between the two companies will enhance Sitero's ability to offer more comprehensive, efficient, and technologically advanced solutions to its clients in the life sciences sector. By incorporating studyOS’s intelligent automation, Sitero aims to streamline data review, improve operational efficiency, and strengthen regulatory compliance for clinical teams.
The combined entity is poised to deliver a more robust and integrated platform, enabling clinical operations and data managers to test protocol adherence, validate site performance, and uncover study patterns instantly. This integration is expected to reduce manual effort, save significant time for clinical teams, and de-risk portfolios for pharmaceutical companies. The forward outlook suggests a stronger position in the clinical research technology market, driving innovation and delivering enhanced value to advance drug development.